PROG Progenity, Inc.

Progenity, Inc.engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent® Carrier Test, Innatal® Prenatal Screen, Riscover® Hereditary Cancer, and Resura® Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

As of 05/12/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/19/2020
Outstanding shares:  60,342,215
Average volume:  446,671
Market cap:   $141,804,205
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74319F107
ISIN:        US74319F1075
Sedol:      BLF0CR2
Valuation   (See tab for details)
PE ratio:   -0.78
PB ratio:   -1.41
PS ratio:   1.91
Return on equity:   179.94%
Net income %:   -259.08%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy